Brainsway Ltd
BWAY15.590USD
0.000
Close 11/07, 16:00（ET）Quotes delayed by 15 min
589.14MMarket Cap
110.24P/E TTM
More Details of Brainsway Ltd Company
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
Brainsway Ltd Info
Ticker SymbolBWAY
Company nameBrainsway Ltd
IPO dateDec 24, 2006
CEOMr. Hadar Levy
Number of employees120
Security typeOrdinary Share
Fiscal year-endDec 24
Address16 Hartum Street Rad Tower, 14Th Floor
CityJERUSALEM
Stock exchangeTel Aviv Stock Exchange
CountryIsrael
Postal code9777516
Phone97225813140
Websitehttps://www.brainsway.com/
Ticker SymbolBWAY
IPO dateDec 24, 2006
CEOMr. Hadar Levy
Company Executives of Brainsway Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Colleen A. Hanlon, Ph.D.
Dr. Colleen A. Hanlon, Ph.D.
Vice President - Medical Affairs
Vice President - Medical Affairs
--
--
Mr. Avner Lushi
Mr. Avner Lushi
Independent Director
Independent Director
--
--
Dr. David Zacut, M.D.
Dr. David Zacut, M.D.
Vice Chairman of the Board
Vice Chairman of the Board
--
--
Mr. Avner Hagai
Mr. Avner Hagai
Independent Director
Independent Director
--
--
Prof. Abraham Zangen, Ph.D.
Prof. Abraham Zangen, Ph.D.
Director
Director
--
--
Mr. Ido Marom
Mr. Ido Marom
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Amiram (Ami) Boehm
Mr. Amiram (Ami) Boehm
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Hadar Levy
Mr. Hadar Levy
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Karen Sarid
Ms. Karen Sarid
Independent Director
Independent Director
--
--
Ms. Eti Michal Mitrany Rayten
Ms. Eti Michal Mitrany Rayten
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Colleen A. Hanlon, Ph.D.
Dr. Colleen A. Hanlon, Ph.D.
Vice President - Medical Affairs
Vice President - Medical Affairs
--
--
Mr. Avner Lushi
Mr. Avner Lushi
Independent Director
Independent Director
--
--
Dr. David Zacut, M.D.
Dr. David Zacut, M.D.
Vice Chairman of the Board
Vice Chairman of the Board
--
--
Mr. Avner Hagai
Mr. Avner Hagai
Independent Director
Independent Director
--
--
Prof. Abraham Zangen, Ph.D.
Prof. Abraham Zangen, Ph.D.
Director
Director
--
--
Mr. Ido Marom
Mr. Ido Marom
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
No Data
By RegionUSD
Name
Revenue
Proportion
United States
33.23M
81.01%
Other
7.79M
18.99%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Valor Equity Partners
13.59%
Masters Capital Management, L.L.C.
5.11%
Phoenix Financial Ltd
3.56%
Acadian Asset Management LLC
1.71%
Essex Investment Management Company, LLC
1.59%
Other
74.44%
Shareholders
Shareholders
Proportion
Valor Equity Partners
13.59%
Masters Capital Management, L.L.C.
5.11%
Phoenix Financial Ltd
3.56%
Acadian Asset Management LLC
1.71%
Essex Investment Management Company, LLC
1.59%
Other
74.44%
Shareholder Types
Shareholders
Proportion
Private Equity
13.98%
Hedge Fund
9.39%
Investment Advisor/Hedge Fund
4.73%
Holding Company
3.67%
Investment Advisor
3.47%
Individual Investor
2.69%
Pension Fund
0.45%
Research Firm
0.31%
Other
61.30%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
83
5.59M
28.96%
-873.84K
2025Q2
82
7.33M
38.85%
+597.38K
2025Q1
84
7.36M
38.96%
-890.13K
2024Q4
77
7.26M
38.54%
-2.72M
2024Q3
65
3.62M
21.68%
-5.03M
2024Q2
59
4.49M
26.92%
-3.10M
2024Q1
56
4.64M
27.89%
-3.35M
2023Q4
48
4.90M
29.50%
-2.87M
2023Q3
43
4.53M
27.32%
-3.32M
2023Q2
45
4.62M
27.86%
-2.51M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Valor Equity Partners
2.10M
11.07%
--
--
Jun 30, 2025
Masters Capital Management, L.L.C.
1.00M
5.26%
--
--
Jun 30, 2025
Phoenix Financial Ltd
697.26K
3.67%
+456.90K
+190.09%
Oct 18, 2024
Acadian Asset Management LLC
334.27K
1.76%
-2.31K
-0.69%
Jun 30, 2025
Essex Investment Management Company, LLC
300.94K
1.58%
-2.23K
-0.73%
Jun 30, 2025
Renaissance Technologies LLC
283.86K
1.49%
-14.40K
-4.83%
Jun 30, 2025
Shulkin (Jonathan K.)
268.25K
1.41%
+268.25K
--
Nov 05, 2024
Gracias (Antonio J)
243.50K
1.28%
+243.50K
--
Nov 05, 2024
ARK Investment Management LLC
199.83K
1.05%
+11.50K
+6.11%
Jun 30, 2025
Two Sigma Investments, LP
172.60K
0.91%
+1.82K
+1.07%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
ActivePassive International Equity ETF
0.04%
ARK Israel Innovative Technology ETF
0%
iShares Neuroscience and Healthcare ETF
0%
ActivePassive International Equity ETF
Proportion0.04%
ARK Israel Innovative Technology ETF
Proportion0%
iShares Neuroscience and Healthcare ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
